Enhancement of apoptosis induction effect of docetaxel by suppressing FABP5 activity in prostate cancer cells
Session type: Poster sessions
Previous work demonstrated that FABP5 is a crucial promoter for the malignant progression of prostate cancer cells. Preliminary study indicated that FABP5 may promote tumorigenicity of the cancer cells through enhancing angiogenesis and suppressing apoptosis. Docetaxel is a common drug used for cancer chemotherapy but its treatment effect on prostate cancer is not as good as on some other cancer types. In this work, we plan to improve the apoptosis-inducing effect of docetaxel by combing it with two FABP5 inhibitors. The possible synergetic effect of different combination amongst the 3 factors will also be investigated.
The moderately and highly malignant prostate cancer cell lines 22Rv1 and PC3 were cultured, treated with either docetaxel alone or in combinations with 1 or 2 of the FABP5 inhibitors and then fluorescently labelled with an Annexin V-FITC apoptosis detection kit (Abcam, UK). The percentages of cells undergo apoptosis in control and in different treatments were detected by flow cytometry.
The preliminary results showed that Docetaxel treatment alone promoted cell apoptosis both on 22Rv1 and PC3 cell lines, the apoptosis rates reached the peak at the concentration of 10nM. Combinations of Docetaxel with either of the 2 FABP5 inhibitors, combinations of any 2 of the 3 factors, or the combination of all 3 factors produced higher apoptosis rates than any single factor alone.
The apoptosis-induction effect of docetaxel can be enhanced by suppressing the biological activity of FABP5.